HDAC9 and cancer: HDACs and SIRTs are important targets for cancer therapy through inhibition of their enzymatic activity by the HDAC and sirtuin inhibitors, which leads to a broad modulation of downstream biological pathways regulated by these proteins [1–3,18–21].